☆ 4.2 Meeting Abstract

A phase 2 trial of the safety and pharmacokinetics of ataluren in patients aged ≥2 to <5 years with nonsense mutation Duchenne muscular dystrophy

NEUROMUSCULAR DISORDERS (2018)

Journal

NEUROMUSCULAR DISORDERS

Volume 28, Issue -, Pages S12-S13

Publisher

PERGAMON-ELSEVIER SCIENCE LTD

DOI: 10.1016/S0960-8966(18)30325-0

Keywords

-

Categories

Clinical Neurology Neurosciences

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

No Data Available

No Data Available

No Data Available

© Peeref 2019-2024. All rights reserved.